Market to Benefit from Increased Adoption of Personalised Medicine in Oncology Sector
Transcriptomics is a study of transcriptomes - entire RNA transcript present in a cell or cell population - to investigate gene expressions. The journey of DNA to protein through mRNA is called gene expression. The field of transcriptomics (study of the mRNA or transcript and related technologies) evolved in the ‘90s with promising approaches to study gene expression. The increasing need for pharmaceutical and biotechnology R&D investment, government funding for omics, and the growing uses of RNA sequencing in the transcriptomics industry are driving the expansion of RNA analysis transcriptomics market. The ever-increasing emphasis on biomarker development and toxico-genomics and the ever-increasing interest in outsourcing services will likely provide significant potential possibilities for companies worldwide in RNA analysis/transcriptomics. The worldwide transcriptomics market's growth is also fuelled by a boost in funding and grants from various private and government organisations.
Rising demand for personalised medicine in cancer treatment and increased R&D expenditure in transcriptomic technologies by pharmaceutical and biotechnology companies are driving the growth of the RNA analysis/transcriptomics market. Personalised medicine has made its way into mainstream clinical practice, changing how many diseases are discovered, categorised, and treated. It has become a primary focus of research in the healthcare industry. These developments are notably visible in cancer. In 2010, in the US, there were 36 drugs available, but by 2020, there were 286 personalised medicines available. In general, the market for tailored medications is expanding. The growing use of personalised medicine will drive the expansion of RNA analysis transcriptomics market.
The demand for personalised medicine is also increasing due to its benefit in oncology treatment. Personalised medicine investigates how a specific gene change (gene mutation) may influence a person's likelihood of developing cancer or, if they already have cancer, how their genes (or genes in their cancer cells) may influence treatment. Thus, helping in the treatment of cancer. In 2020, there will be an estimated 18.1 million cancer cases worldwide. Men made up 9.3 million cases, while women made up 8.8 million. The growing prevalence of cancers will boost the demand for personalised medicine, thus driving the growth of RNA analysis transcriptomics market.
Reagents Continue to Dominate RNA Analysis Transcriptomics Market with a Phenomenal Binding Property
The kits and reagents segment will have the highest revenue share in the forecast period. The category is growing due to the rising demand for high-quality reagents and kits and the frequent use of reagents and media in transcriptome research. High-quality reagents and kits contribute to unrivalled efficiency and performance, ensuring reliable and reproducible sequencing results at a low cost. Growing R&D efforts in the pharmaceutical sector and increased government spending on life science research are likely to drive this segment in RNA analysis transcriptomics market. High research and development expenses by biotechnology companies, an increase in the number of biotechnology firms, an increase in biopharmaceuticals, and technological advancements are projected to drive the growth of the reagents segment during the forecast period. The rising use of biotechnology reagents in medicines, commercial applications, and fundamental research are just a few of the factors expected to drive the growth of the reagents sector.
Higher Expenditure on Medical Research Largely Account for North America’s Prime Position in RNA Analysis Transcriptomics Market
In the forecast period, North America will have the highest revenue share. The increased development of structure-based drug designs, growing academic and government investments in genomics and proteomics research, high life science research funding, high biopharmaceutical R&D expenditure, and greater adoption of advanced technologies in North America contribute to the growth. Rebus Biosystems debuted its spatial transcriptomics analysis platform spatial omics technology in 2021, allowing researchers to examine individual cells' output across tissue samples. Such product introductions will have a favourable impact on the region’s RNA analysis transcriptomics market. The private sector's ongoing increase in transcriptomics-related research and development spending enables regional market players to create tailored therapies. Another important reason is contributing to this RNA analysis transcriptomics market segment's significant share in the presence of many global players in this region.
Asia Pacific is predicted to rise at a considerable rate during the forecast period due to the region's growing number of pharmaceutical and biotechnology businesses, which will lead to increased demand for transcriptomics technologies and investments in R&D and drug development. The Chinese pharmaceutical sector is also highly fragmented, with roughly 5,000 pharmaceutical producers, the vast majority of which are small and medium-sized businesses. Growing government and private sector investments boost biotechnology research in Asia Pacific countries. The Japanese government and non-governmental organisations are strongly supportive of the country's biotechnology research and give funding for research in medical and life sciences. This encourages researchers to investigate the field of transcriptomics aggressively.
Global RNA Analysis Transcriptomics Market: Competitive Landscape
Participants in the market are releasing new products and developing alliances, collaborations, and partnership agreements. In February 2021, Parse Biosciences introduced the Single Cell Whole Transcriptome Kit. The kit, previously only available through Parse's early access program, is now open to all North American researchers. In September 2020, Agilent Technologies Inc. (NYSE: A) announced today the availability of the SureSelect XT HS2 RNA Reagent Kit. This system has a modular design that allows for a straightforward and parallel approach for RNA and DNA samples, allowing clients to streamline and consolidate their workflow without wasting time optimising multiple kits for different sample types.
Few of the players in the RNA analysis transcriptomics market include Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Danaher Corporation (US), Fluidigm Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Sequentia Biotech SL (Spain), Eurofins Scientific (Germany), GenXPro GmbH (Germany), Acobiom (France), bioMérieux SA (France), CD Genomics (US), Lexogen GmbH (Austria), Promega Corporation (US), Takara Holdings, Inc. (Japan), Cenix BioScience GmbH (Germany), and LC Sciences LLC (US).
Global RNA Analysis Transcriptomics Market is Differentiated as below:
By End User
Key Elements Included In The Study: Global RNA Analysis Transcriptomics Market
Post Sale Support, Research Updates & Offerings
We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.
Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.Read more